Cargando…

FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection

BACKGROUND: Herpes simplex virus type 2 (HSV-2) is a leading cause of genital ulceration that can predispose individuals to an increased risk of acquiring other sexually transmitted infections. There are no approved HSV-2 vaccines and current suppressive therapies require daily compound administrati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rose, William A, McGowin, Chris L, Pyles, Richard B
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780411/ https://www.ncbi.nlm.nih.gov/pubmed/19903337 http://dx.doi.org/10.1186/1743-422X-6-195

Ejemplares similares

The Toll–Like Receptor 2/6 Agonist, FSL–1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome
por: Kurkjian, Cathryn J., et al.
Publicado: (2017)

FSL-1, a Toll-like Receptor 2/6 Agonist, Induces Expression of Interleukin-1α in the Presence of 27-hydroxycholesterol
por: Heo, Weon, et al.
Publicado: (2014)

Multiple Signaling Molecules are Involved in Expression of CCL2 and IL-1β in Response to FSL-1, a Toll-Like Receptor 6 Agonist, in Macrophages
por: Won, Keunsoo, et al.
Publicado: (2012)

Intracellular Mycoplasma genitalium infection of human vaginal and cervical epithelial cells elicits distinct patterns of inflammatory cytokine secretion and provides a possible survival niche against macrophage-mediated killing
por: McGowin, Chris L, et al.
Publicado: (2009)

Commensal Bacteria Modulate Innate Immune Responses of Vaginal Epithelial Cell Multilayer Cultures
por: Rose, William A., et al.
Publicado: (2012)

Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
por: Schintu, Nicoletta, et al.
Publicado: (2020)

Mycoplasma genitalium: An Emerging Cause of Sexually Transmitted Disease in Women
por: McGowin, Chris L., et al.
Publicado: (2011)

FSL‐MRS: An end‐to‐end spectroscopy analysis package
por: Clarke, William T., et al.
Publicado: (2020)

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

432. Qualitative Differentiation of Genital Ulcer Disease Etiology via Nucleic Acid Amplification Testing (NAAT)
por: McGowin, Chris L, et al.
Publicado: (2019)

Toll-like receptor 2 agonists inhibit human fibrocyte differentiation
por: Maharjan, Anu S, et al.
Publicado: (2010)

Quantitative Comparison of SPM, FSL, and Brainsuite for Brain MR Image Segmentation
por: Kazemi, K, et al.
Publicado: (2014)

Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants
por: Kumar, Sudeep, et al.
Publicado: (2019)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Transcriptomal signatures of vaccine adjuvants and accessory immunostimulation of sentinel cells by toll-like receptor 2/6 agonists
por: Salyer, Alex C. D., et al.
Publicado: (2018)

Toll-like receptor 2 agonist exacerbates renal injury in diabetic mice
por: Li, Fanglin, et al.
Publicado: (2017)

Altered explorative strategies and reactive coping style in the FSL rat model of depression
por: Magara, Salvatore, et al.
Publicado: (2015)

Comparison of accuracy between FSL’s FIRST and Freesurfer for caudate nucleus and putamen segmentation
por: Perlaki, Gabor, et al.
Publicado: (2017)

Fully automated open‐source lesion mapping of T2‐FLAIR images with FSL correlates with clinical disability in MS
por: Wetter, Nathan C., et al.
Publicado: (2016)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Impact of Selected Bacterial and Viral Toll-like Receptor Agonists on the Phenotype and Function of Camel Blood Neutrophils
por: Hussen, Jamal, et al.
Publicado: (2023)

416. Comparative Analytical Assessment of PCR Mastermixes for Detection of SARS-CoV-2 using the CDC Diagnostic Test and the LightMix Modular Test on the cobas® z 480 Analyzer
por: Cagas, Steven, et al.
Publicado: (2020)

Reproducing FSL's fMRI data analysis via Nipype: Relevance, challenges, and solutions
por: Chen, Yibei, et al.
Publicado: (2022)

Preconditioning of Rat Bone Marrow-Derived Mesenchymal Stromal Cells with Toll-Like Receptor Agonists
por: Evaristo-Mendonça, Fabiana, et al.
Publicado: (2019)

Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases
por: Gu, Yangzhuo, et al.
Publicado: (2023)

FOXO1 inhibits FSL-1 regulation of integrin β6 by blocking STAT3 binding to the integrin β6 gene promoter
por: Xu, Mingyan, et al.
Publicado: (2022)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

Extracellular Ribosomal RNA Acts Synergistically with Toll-like Receptor 2 Agonists to Promote Inflammation
por: Grote, Karsten, et al.
Publicado: (2022)

Human Toll-like Receptor 2 Confers Responsiveness to Bacterial Lipopolysaccharide
por: Kirschning, Carsten J., et al.
Publicado: (1998)

Erratum to “Preconditioning of Rat Bone Marrow-Derived Mesenchymal Stromal Cells with Toll-Like Receptor Agonists”
por: Evaristo-Mendonça, Fabiana, et al.
Publicado: (2020)

Differential modulation of cysteinyl leukotriene receptor 1 and 2 expression by distinct Toll-like receptor agonists in monocyte-derived dendritic cells
por: Rola-Pleszczynski, M, et al.
Publicado: (2004)

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
por: Chan, Michael, et al.
Publicado: (2009)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
por: Macedo, Amanda B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b1ug0icb8ns1os62jllllqolh4